Tyra Biosciences (TYRA) Change in Accured Expenses (2020 - 2026)

Tyra Biosciences has reported Change in Accured Expenses for 7 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 427.4% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (down 14.97% YoY), and the FY2025 full-year result was $3.4 million, up 552.82% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $1.2 million, down from $2.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.1 million in Q4 2023, with the low at -$6.9 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $914470.6 across 5 years, with a median of $1.6 million in 2022.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 9572.92% — and 2024, when it plunged 241.54%.
• Tyra Biosciences' Change in Accured Expenses stood at $207000.0 in 2022, then soared by 2352.17% to $5.1 million in 2023, then slumped by 56.5% to $2.2 million in 2024, then declined by 2.36% to $2.2 million in 2025, then plunged by 44.57% to $1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.2 million (Q1 2026), $2.2 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.